Semaglutide for MASH: what the ESSENCE trial and the FDA approval actually say

For a decade, fatty-liver disease was the graveyard of drug development — trial after trial failed to move liver histology. Then two things happened in quick succession: a dedicated liver drug got approved, and the biggest GLP-1 of all showed it could clear the disease too. In August 2025 the FDA approved Wegovy (semaglutide 2.4 mg) for a specific slice of MASH, making it the first GLP-1 receptor agonist cleared for the indication.^[3] Here is precisely what the evidence shows, what it does not, and exactly which patients the label covers.

What MASH is, and why the liver was so hard to fix

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the umbrella term for fat accumulation in the liver driven by metabolic dysfunction — the condition long called non-alcoholic fatty liver disease. MASH (metabolic dysfunction-associated steatohepatitis, formerly NASH) is its aggressive form: fat plus inflammation plus liver-cell injury, the stage that drives fibrosis (scarring) and can end in cirrhosis, liver cancer or transplant. The endpoints that matter clinically are therefore two distinct things: resolution of the steatohepatitis (clearing the inflammation) and improvement of fibrosis (reversing the scar). They are not the same, and fibrosis is the harder one to shift.

The mechanism: mostly an indirect, metabolic effect

Semaglutide is not a liver drug in the direct sense — the therapeutic effect on the liver is thought to run largely through the same machinery that drives its weight and glucose results, covered in our semaglutide weight-loss trials review. Substantial weight loss, improved insulin sensitivity and lower glycemia reduce the delivery of fat to the liver and dampen the inflammatory milieu, which allows steatohepatitis to resolve. Fibrosis is downstream of all that and slower to remodel — which is exactly why a drug can clear the inflammation while barely touching the scar. Keep that hierarchy in mind; it explains the gap between the Phase 2 and Phase 3 results.

Phase 2 (2021): resolution yes, fibrosis no

The proof-of-concept was a 72-week Phase 3-quality Phase 2 trial of once-daily subcutaneous semaglutide (up to 0.4 mg/day) in biopsy-confirmed NASH. On the primary endpoint — resolution of steatohepatitis with no worsening of fibrosis — the top dose was clearly superior to placebo (59% vs 17%).^[2] But the trial did not show a significant benefit on the fibrosis endpoint: the proportion of patients with fibrosis improvement was not statistically different from placebo.^[2] That missed endpoint is the honest asterisk on the early story — it left open the central question of whether a GLP-1 could actually reverse liver scarring, not just calm the inflammation.

ESSENCE (2025): both endpoints met

ESSENCE is the Phase 3 trial that answered it. In the pre-specified 72-week analysis of roughly 800 adults with MASH and moderate-to-advanced fibrosis (stage F2–F3), the once-weekly 2.4 mg dose met both primary endpoints. Resolution of steatohepatitis without worsening of fibrosis occurred in 62.9% on semaglutide versus 34.3% on placebo; improvement in liver fibrosis without worsening of steatohepatitis occurred in 36.8% versus 22.4%.^[1] The fibrosis win is the headline — it is the endpoint the earlier trial missed, and the harder one to move. As with every GLP-1 program, gastrointestinal side effects were the most common adverse events, and rapid weight loss carries its own downstream considerations such as the gallbladder risk we cover separately.

Two caveats keep the read honest. First, ESSENCE is a histology trial reporting surrogateendpoints — biopsy-scored resolution and fibrosis — not hard clinical outcomes like cirrhosis, transplant or death; those are what the longer-term part of the program is designed to confirm. Second, the trial enrolled the F2–F3 population specifically, so the result speaks to that group, not to milder fatty liver or to established cirrhosis.

The regulatory reality — stated precisely

On August 15, 2025 the FDA granted accelerated approval to Wegovy (semaglutide 2.4 mg) for adults with noncirrhotic MASH with moderate-to-advanced liver fibrosis, to be used alongside a reduced-calorie diet and increased physical activity.^[3] Precision matters here, because it is easy to overstate:

• It is the first GLP-1 approved for MASH — a genuine first.^[3]
• The indication is noncirrhotic MASH with F2–F3 fibrosis only — not simple fatty liver (MASLD without significant fibrosis), and explicitly not compensated or decompensated cirrhosis.^[3]
• It is an accelerated approval based on the surrogate histology endpoints, meaning continued approval can hinge on confirmatory clinical-outcome data.^[3]

So the accurate one-liner is: semaglutide 2.4 mg is approved for MASH, but for a defined F2–F3 population and under the accelerated pathway — not as a blanket “fatty-liver drug.”

How it sits among the dedicated MASH agents

Semaglutide is not the only — or the first — drug to reach this space. The first drug approved for MASH was resmetirom (Rezdiffra), a liver-directed thyroid-hormone-receptor-beta agonist cleared by the FDA in March 2024 for the same noncirrhotic F2–F3 population.^[4] It remains the dedicated, purpose-built MASH therapy. Alongside it, the GLP-1/glucagon dualagonists are being developed specifically for the liver: survodutide showed improvement in MASH and, encouragingly, a fibrosis signal in its Phase 2 trial,^[5] and pemvidutide reported Phase 2b MASH data as well.^[6] The glucagon arm of these molecules is a deliberate liver play — glucagon-receptor agonism drives hepatic fat mobilization — which is why the duals are watched closely in this indication.

For patients weighing options, the practical framing is that MASH now has both a dedicated agent (resmetirom) and a metabolic one (semaglutide), with more incretin-based candidates behind them. If weight and metabolic disease dominate the picture, a GLP-1 that treats both is attractive; how the potent incretins compare on the weight axis specifically is laid out in our tirzepatide versus semaglutide comparison.

The honest bottom line

The evidence here is genuinely strong — Phase 3, two met endpoints, including the fibrosis endpoint an earlier trial missed. That is a real advance, and the FDA approval is real. But it is a targeted approval for noncirrhotic F2–F3 MASH under the accelerated pathway on surrogate histology, not a universal fatty-liver cure, and the long-term clinical-outcomes data are still to come. For the right patient — significant fibrosis, significant metabolic disease — semaglutide is now a legitimate, evidence-backed option. For everyone else with “fatty liver,” it is not yet, and the distinction is the whole point.